Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Pile of papers on a desk

Launching in the February issue of Nature Reviews Immunology, the Preprint Watch column is designed to provide rapid and open access to early data on both COVID-19 and non-COVID-19 immunology preprints. The first two reviews are: Super(antigen) target for SARS-CoV-2 and Sensing our Z-RNA.

During the COVID-19 pandemic the pace of scientific discovery and the race to find solutions required swift communication of results and fuelled an increase in immunology preprints. Journal club communities around the world seized the opportunity to evaluate and critically analyse a large number of SARS-CoV-2 preprints to provide independent insights to frontline researchers, to the general public, and to help prevent misinformation.

The journal group at Precision Immunology Institute at the Icahn School of Medicine, New York, and the OxImmuno Literature Initiative at the University of Oxford were both producing regular preprint summaries related to the COVID-19 emergency. Towards the end of 2020, the journal club teams from both institutes joined forces to launch the Oxford-Mount Sinai (OxMS) preprint journal club. During a weekly virtual joint ‘journal club’ they discuss selected preprints using their cross-institutional expertise and find the latest advancement in immunology. This new way of assessing and reviewing preprint literature may become a new approach to academic peer reviewing.

Felix Richter, Wellcome Trust DPhil student and co-founder of the OxMS Journal Club initiative at NDORMS said: “We are very happy to have started the first cross-institutional preprint journal club in collaboration with Nature Reviews Immunology and our colleagues at Mount Sinai School of Medicine. The aim of this community-based initiative is to identify trends in up-and-coming literature in immunology. It further provides a training opportunity for early career researchers to assess primary research data and provide constructive feedback to peers in the field.  We hope it will be of benefit to the preprint authors by providing useful suggestions to improve their research and by highlighting their research strengths.

We believe that other journal clubs around the world can use our approach to create more of these ‘preprint club hubs’ for immunology or other fields of science. The partnership with other international Institutes, publishers and organisations specialised on providing peer-review training to early career researchers is key to the success of this initiative.”

The launch edition of the Preprint Watch column comes with an editorial from Nature Reviews Immunology that explains the rationale for covering preprints and the precautions that must be considered with their use.

 

 

 

Similar stories

NDORMS researchers awarded ECTS prizes

Awards Kennedy Main

Professor Anjali Kusumbe and Professor Cyrus Cooper have been presented with research awards by the European Calcified Tissue Society (ECTS).

New children’s orthopaedic hospital opens in Zimbabwe

Main

A new children’s orthopaedic hospital in Bulawayo that will treat children across Zimbabwe who are living with musculoskeletal impairments has opened today.

Professor Katja Simon elected to the Academy of Medical Sciences

Awards Kennedy Main

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.